ArticleJNCI cancer spectrum2022

Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.

Vanessa Arciero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.